1.94
Schlusskurs vom Vortag:
$2.10
Offen:
$2.12
24-Stunden-Volumen:
163.23K
Relative Volume:
0.08
Marktkapitalisierung:
$13.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.46M
KGV:
-0.1386
EPS:
-14
Netto-Cashflow:
$-24.56M
1W Leistung:
-21.74%
1M Leistung:
-54.69%
6M Leistung:
-86.84%
1J Leistung:
-89.18%
Evaxion Biotech A S Adr Stock (EVAX) Company Profile
Firmenname
Evaxion Biotech A S Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie EVAX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
EVAX
Evaxion Biotech A S Adr
|
1.94 | 13.16M | 0 | -11.46M | -24.56M | -14.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Evaxion Biotech A S Adr Stock (EVAX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-04-02 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
2024-02-12 | Eingeleitet | H.C. Wainwright | Buy |
Evaxion Biotech A S Adr Aktie (EVAX) Neueste Nachrichten
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
Evaxion Biotech A/SADR to Host Earnings Call - ACCESS Newswire
Evaxion Biotech stock hits 52-week low at $2.22 amid sharp decline - Investing.com
Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading - TradingView
Evaxion Biotech A/S ADR (EVAX) Receives Upgrades Amid Sharp Decline – Is It Time for Investors to Reevaluate? - HPBL
Evaxion Biotech (EVAX) Stock Analysis: Price Decline, Analyst Ratings and Financial Ratios – market - HPBL
European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading - TradingView
After A Decline Of -818.6% From The High, Can Evaxion Biotech A/S ADR (NASDAQ: EVAX) Recover Quickly? - Marketing Sentinel
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, End Week Up 3.2% - TradingView
Top investors say Evaxion Biotech A/S ADR (EVAX) ticks everything they need - SETE News
Evaxion Biotech A/S ADR [EVAX] Investment Guide: What You Need to Know - Knox Daily
Now Is The Time To Build A Position In Evaxion Biotech A/S ADR (NASDAQ:EVAX) - Marketing Sentinel
Evaxion Biotech A/S ADR (EVAX) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Palantir Technologies Surges 16.5% in Pre-Market Trading After Strong Q4 Earnings Report - HPBL
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView
Spyre Therapeutics Inc (SYRE) stock analysis: A comprehensive overview - US Post News
Argo Blockchain Plc ADR (ARBK)’s stock price in review: A technical analysis - US Post News
Evaxion Biotech A/S ADR (EVAX)’s stock decline to 2.40 per share - US Post News
Daily Market Movement: Onconetix Inc (ONCO) Sees a 11.91 Increase, Closing at 0.61 - The Dwinnex
In the Green: Evaxion Biotech A/S ADR (EVAX) Closes at 2.40, Up/Down -2.24 from Previous Day - The Dwinnex
Market Insights: Kairos Pharma Ltd (KAPA)’s Notable Gain of 6.29, Closing at 1.52 - The Dwinnex
Palantir Technologies at a Crossroads: Sky-High Valuation or Looming Market Correction? - HPBL
Hodges Capital Management Takes $16.5 Million Stake in Palantir Technologies (PLTR) – market - HPBL
H.C. Wainwright maintains Evaxion stock Buy rating, $14 target - Investing.com
Major Pharma Giant's VC Fund Doubles Down on Evaxion Biotech in $10.8M Strategic Round - StockTitan
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading - TradingView
Evaxion Biotech stock hits 52-week low at $2.38 amid market challenges - Investing.com
European Equities Traded in the US as American Depositary Receipts Tread Water in Monday Trading - MSN
When Will Evaxion Biotech A/S ADR. (EVAX) Be Worth Investing In? - Marketing Sentinel
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Gains 2% for Week - MSN
Investing Now Could Prove Beneficial For Evaxion Biotech A/S ADR (NASDAQ: EVAX) - Marketing Sentinel
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading - MSN
Future Outlook And Stock Price Performance For Evaxion Biotech A/S ADR (NASDAQ: EVAX) - Marketing Sentinel
Evaxion Biotech stock hits 52-week low at $3.06 amid sharp decline By Investing.com - Investing.com South Africa
Evaxion Biotech stock hits 52-week low at $3.06 amid sharp decline - Investing.com
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN
Evaxion Biotech Completes 1:5 Reverse ADS Split: What Investors Need to Know - StockTitan
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Tuesday Trading - MSN
Evaxion Biotech stock hits 52-week low at $0.81 amid market challenges - Investing.com India
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Flat for Week - MSN
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading - MSN
Evaxion Biotech Announces 1:5 ADS Ratio Change, Effective January 2025 - StockTitan
European Equities Traded in the US as American Depositary Rise in Monday Trading - MSN
European Equities Traded in the US as American Depositary Rise in Thursday Trading - MSN
European Equities Traded in US as American Depositary Receipts Tread Water Friday, Up 3% for Week - MSN
European Equities Traded in the US as American Depositary Edge Higher in Thursday Trading - MSN
Evaxion Biotech stock hits 52-week low at $0.84 amid market challenges - Investing.com
Finanzdaten der Evaxion Biotech A S Adr-Aktie (EVAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):